New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
08:32 EDTTHORThoratec announces First HeartMate III Human Implant and start of CE Mark trial
Thoratec said that its CE Mark Clinical Trial for HeartMate III commenced with the first patient implanted with this new device. HeartMate III is a centrifugal-flow chronic left ventricular assist system. The fully magnetically levitated technology foundation of HeartMate III is designed to lower adverse event rates through improved hemocompatibility while enhancing ease of surgical placement through a compact size.
News For THOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
10:24 EDTTHORThoratec price target raised to $53-$54 from $48-$50 at Wells Fargo
Subscribe for More Information
09:04 EDTTHORThoratec receives conditional FDA approval for Shield II U.S. trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use